Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations.
Sign Up to like & getrecommendations! Published in 2021 at "Thoracic cancer"
DOI: 10.1111/1759-7714.14156
Abstract: BACKGROUND Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have improved the prognosis of mutant lung cancer; however, the clinical application value of TKIs for nonclassical EGFR mutation is unclear, especially for patients with… read more here.
Keywords: response; treatment; uncommon mutations; rare uncommon ... See more keywords
Mechanisms of primary resistance to icotinib in Chinese non-small-cell lung cancer patients with EGFR uncommon mutations: A multicenter study.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.e20501
Abstract: e20501 Background: Previous case series, retrospective studies and pooled survey studies have investigated the clinical efficacies of EGFR-TKIs in patients harboring EGFR uncommon mutations. However, part of patients with EGFR uncommon mutations do not exhibit… read more here.
Keywords: primary resistance; uncommon mutations; resistance icotinib; egfr uncommon ... See more keywords